Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, limiting the production of tetrahydrofolate needed for DNA and RNA synthesis. By reducing nucleic acid formation, it slows the proliferation of rapidly dividing cells, including immune cells involved in inflammation and malignant tumor cells.

The dose of Metoject is individualized and set by the prescribing healthcare professional. Dosing depends on the indication, patient weight, renal function, and response to therapy. Patients should follow the exact regimen provided by their physician.

Methotrexate is generally contraindicated in pregnancy because of its known teratogenic potential. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after stopping therapy. Breastfeeding is also discouraged unless the prescriber determines the benefits outweigh the risks.

To request Metoject, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and import documentation.

Methotrexate, the active ingredient in Metoject, is a first‑line antimetabolite that offers oral and subcutaneous options, whereas many biologic agents target specific cytokines and require intravenous infusion. Methotrexate is generally less expensive but may have a broader side‑effect profile, requiring regular laboratory monitoring.

Metoject should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the product. Do not store at room temperature for extended periods.

Metoject is supplied as a sterile solution for subcutaneous injection. A healthcare professional prepares the dose using aseptic technique and injects it into the subcutaneous tissue, typically in the abdomen or thigh, according to the prescriber’s instructions.

Serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow suppression leading to pancytopenia, acute renal failure, and life‑threatening infections. Patients should be monitored regularly for signs of organ dysfunction and advised to report any unusual symptoms promptly.

Metoject is contraindicated in patients with known hypersensitivity to methotrexate, severe renal or hepatic impairment, uncontrolled infections, and in women who are pregnant or planning to become pregnant without effective contraception. The prescriber will assess individual risk factors before initiating therapy.